Harrow named Amir H. Shojaei, PharmD, PhD, as its chief scientific officer (CSO). Dr. Shojaei brings deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, including work in anterior and posterior segment ophthalmic drug indications.

Dr. Shojaei most recently served as CSO and executive vice president of clinical development at AsclepiX Therapeutics. Prior to that, he held senior executive roles, including CEO, at TherOptix Corporation, where he advanced a drug-eluting contact lens platform. Additionally, he held various leadership roles at Novartis Pharmaceuticals and Shire Pharmaceuticals (acquired by Takeda).

Dr. Shojaei succeeds Dennis E. Saadeh, PharmD, who is retiring after nearly a decade of service to Harrow, including from his most recent role as CSO.